Evidence map›Paper›PMID 32511953›Full record

ArticleExperimental neurology2020

Chronic defects in intraspinal mechanisms of spike encoding by spinal motoneurons following chemotherapy.

Stephen N Housley, Paul Nardelli, Randal K Powers, Mark M Rich, Timothy C Cope

Open access · greenAbstract read
In one paragraph

Article in Experimental neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Structural Preservation Does Not Ensure Function at Sensory Ia-Motoneuron Synapses following Peripheral Nerve Injury and Repair.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  6. Article
  7. Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2022
    Article
  8. Article
  9. Article
  10. Neural circuit mechanisms of sensorimotor disability in cancer treatment.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  11. Article
  12. A review of movement disorders in chemotherapy-induced neurotoxicity.Journal of neuroengineering and rehabilitation · 2021
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Stephen N HousleySchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30318, USA.
Paul NardelliSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30318, USA.
Randal K PowersDepartment of Physiology and Biophysics, University of Washington, Seattle, WA 98195, USA.
Mark M RichDepartment of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, OH 45435, USA.
Timothy C CopeSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30318, USA; Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30318, USA. Electronic address: tim.cope@gatech.edu.
Georgia Institute of Technology · USUniversity of Washington · USWright State University · US

Funding

Novel Approaches to Therapy of Muscle Ion ChannelopathiesR01AR074985 · NIAMS · WRIGHT STATE UNIVERSITY · PI MARK M RICH · 2019 to 2026
$3.9M
Novel Path to Chronic Sensorimotor Dysfunction and Treatment for ChemotherapyR01CA221363 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI COPE, TIMOTHY C · 2018 to 2022
$1.5M
NCI NIH HHS R01 CA221363NIAMS NIH HHS R01 AR074985
6 · The paper itself

Abstract

Chemotherapy-induced sensorimotor disabilities, including gait and balance disorders, as well as physical fatigue often persist for months and sometimes years into disease free survival from cancer. While associated with impaired sensory function, chronic sensorimotor disorders might also depend on chemotherapy-induced defects in other neuron types. In this report, we extend consideration to motoneurons, which, if chronically impaired, would necessarily degrade movement behavior. The present study was undertaken to determine whether motoneurons qualify as candidate contributors to chronic sensorimotor disability independently from sensory impairment. We tested this possibility in vivo from rats 5 weeks following human-scaled treatment with one of the platinum-based compounds, oxaliplatin, widely used in chemotherapy for a variety of cancers. Action potential firing of spinal motoneurons responding to different fixed levels of electrode-current injection was measured in order to assess the neurons' intrinsic capacity for stimulus encoding. The encoding of stimulus duration and intensity corroborated in untreated control rats was severely degraded in oxaliplatin treated rats, in which motoneurons invariably exhibited erratic firing that was unsustained, unpredictable from one stimulus trial to the next, and unresponsive to changes in current strength. Direct measurements of interspike oscillations in membrane voltage combined with computer modeling pointed to aberrations in subthreshold conductances as a plausible contributor to impaired firing behavior. These findings authenticate impaired spike encoding as a candidate contributor to, in the case of motoneurons, deficits in mobility and fatigue. Aberrant firing also becomes a deficit worthy of testing in other CNS neurons as a potential contributor to perceptual and cognitive disorders induced by chemotherapy in patients.

Indexed as

AnimalsAntineoplastic AgentsComputer SimulationFemaleModels, NeurologicalMotor NeuronsOxaliplatinRatsRats, WistarSpinal CordAntineoplastic AgentsOxaliplatinCentral nervous systemChemotherapyCNSComputer modelingEncodingFiring behaviorImpaired excitabilityMotoneuronsRate-modulationSubthreshold oscillations

Identifiers

PMID32511953
PMCPMC7937189
OpenAlexW3033374745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.